Heron Therapeutics
HRTX
180 hedge funds and large institutions have $1.69B invested in Heron Therapeutics in 2019 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 73 increasing their positions, 39 reducing their positions, and 24 closing their positions.
87% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 39
48% more call options, than puts
Call options by funds: $8.62M | Put options by funds: $5.82M
21% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 24
2% more funds holding
Funds holding: 176 → 180 (+4)
3% less capital invested
Capital invested by funds: $1.74B → $1.69B (-$52.9M)
3.99% less ownership
Funds ownership: 118.54% → 114.55% (-4%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| 1 |
Franklin Resources
San Mateo,
California
|
+$18.6M |
| 2 |
ClearBridge Investments
New York
|
+$13.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.63M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$7.3M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$6.22M |
Top Sellers
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$26.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$24.8M |
| 3 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
-$23.7M |
| 4 |
BC
Broadfin Capital
New York
|
-$10.3M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$9.45M |
HRTX Hedge Fund Activity: Q3 2019 in Review
180 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q3 2019, worth a combined $1.69B — down 3% from $1.74B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new HRTX positions and 24 closed out — a net gain of 5 holders — while 73 added to existing stakes and 39 trimmed.
The largest buyer was Franklin Resources, adding an estimated $18.6M. The largest seller was Eagle Asset Management, exiting entirely with an estimated $26.7M sold.
- 180 institutional investors held Heron Therapeutics (HRTX) as of Q3 2019, up from 176 in Q2 2019.
- Funds reported $1.69B of Heron Therapeutics stock for Q3 2019, down 3% quarter-over-quarter.
- 29 funds opened new Heron Therapeutics positions in Q3 2019 and 24 closed out, a net change of +5 holders.
- The largest Heron Therapeutics buyer in Q3 2019 was Franklin Resources, an estimated $18.6M added.
- The largest Heron Therapeutics seller in Q3 2019 was Eagle Asset Management, an estimated $26.7M sold.
Based on aggregated 13F filings for Q3 2019.